Martorell

This study is designed to identify individuals who may be eligible for future Roche clinical trials focused on Alzheimer's disease. It serves as a pre-screening step to evaluate participants based on biomarker status and cognitive performance. The study targets adults aged 50 to 90 years who have experienced memory concerns recently, with or without a diagnosis of mild cognitive impairment or dementia due to Alzheimer's disease. Participants do not receive any intervention during this study. Instead, they will have their blood drawn to measure the concentration of a biomarker called pTau217 and will undergo a cognitive assessment using the ISLT (International Shopping List Test) on the first day of participation. This process helps researchers determine potential eligibility for more extensive Alzheimer's disease trials. During the study, participants will be evaluated for memory concerns and cognitive function through blood tests and cognitive scoring. Researchers will monitor biomarker levels and cognitive scores on the first day to help assess trial eligibility. The study includes safety assessments to ensure participants can safely complete these procedures, with participation lasting for the duration of the pre-screening evaluations.

This research evaluates the addition of immunotherapy drugs atezolizumab and tiragolumab to standard chemoradiotherapy for patients with localized squamous cell carcinoma of the anal canal. The study is a Phase II, single-arm, open-label trial focusing on patients who have not received prior treatment. It aims to improve the rate of complete tumor response and reduce relapse by enhancing immune system recognition of tumor antigens. All participants will receive two cycles of atezolizumab (1200 mg) plus tiragolumab (600 mg) alongside six weeks of standard chemoradiotherapy including cisplatin, 5-fluorouracil, and radiotherapy. Following this, patients enter a consolidation phase lasting up to 24 weeks during which they continue treatment with atezolizumab and tiragolumab. Treatment is stopped if disease progression, toxicity, or other criteria require discontinuation. During the study, patients will undergo clinical evaluations to measure tumor response by biopsy and imaging at week 26. Researchers will assess the clinical complete response rate as the main outcome, as well as survival rates, safety, and quality of life. Biomarker studies on tumor and blood samples will explore molecular predictors of response. Follow-up will continue to monitor disease control, side effects, and patient well-being throughout and beyond treatment.